Latest Mifepristone Stories
According to a report published Monday, giving birth can be far more hazardous to a woman’s health than obtaining a legal abortion, noting that pregnant women were up to 14 times more likely to die due to complications associated with childbirth compared to abortions.
Corcept Therapeutics (NASDAQ: CORT) released their final Phase 3 data for Corlux in mid-January, concluding a successful clinical trial. The next anticipated milestone is submission of the New Drug Application to the U.S. Food and Drug Administration.
Research continues to show that the controversial abortion drug mifepristone might have another use, as a therapeutic option besides hysterectomy for women who suffer from severe symptoms associated with uterine fibroids.